Delcath Systems (DCTH) Projected to Post Quarterly Earnings on Tuesday

Delcath Systems (NASDAQ:DCTH) will likely be issuing its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $23.2180 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:30 AM ET.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.05. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%.The firm had revenue of $24.16 million during the quarter, compared to analyst estimates of $22.84 million. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Delcath Systems Stock Performance

DCTH opened at $9.83 on Friday. The business has a 50 day moving average price of $10.95 and a 200 day moving average price of $12.36. Delcath Systems has a twelve month low of $8.87 and a twelve month high of $18.23. The firm has a market cap of $343.86 million, a P/E ratio of 196.60 and a beta of 0.84.

Wall Street Analyst Weigh In

DCTH has been the subject of several analyst reports. Craig Hallum restated a “buy” rating and issued a $20.00 target price on shares of Delcath Systems in a report on Tuesday, October 21st. HC Wainwright set a $30.00 target price on Delcath Systems and gave the stock a “buy” rating in a report on Monday, October 20th. Canaccord Genuity Group restated a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a report on Tuesday, October 21st. Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a research report on Sunday, October 12th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Delcath Systems in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DCTH. Rosalind Advisors Inc. increased its position in shares of Delcath Systems by 13.8% during the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after purchasing an additional 400,000 shares during the period. Marshall Wace LLP bought a new stake in shares of Delcath Systems during the second quarter valued at approximately $6,572,000. Millennium Management LLC increased its position in shares of Delcath Systems by 34.1% during the first quarter. Millennium Management LLC now owns 422,066 shares of the company’s stock valued at $5,373,000 after purchasing an additional 107,391 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Delcath Systems by 8.4% during the second quarter. Cubist Systematic Strategies LLC now owns 306,300 shares of the company’s stock valued at $4,166,000 after purchasing an additional 23,762 shares during the period. Finally, Jump Financial LLC increased its position in shares of Delcath Systems by 604.9% during the second quarter. Jump Financial LLC now owns 197,466 shares of the company’s stock valued at $2,686,000 after purchasing an additional 169,453 shares during the period. 61.12% of the stock is owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.